The Hydrus Microstent is a highly flexible, biocompatible 8mm long device delivered ab interno into the trabecular meshwork and Schlemm’s canal. The Hydrus Microstent, in conjunction with cataract surgery, has been clinically proven to reduce intraocular pressure (IOP) and medication usage.1,2 It is the first and only minimally invasive glaucoma surgery (MIGS) device to report clinical results from a pivotal trial at five years.2,3* The study included 556 patients at 38 centres from nine countries with 66% of Hydrus Microstent patients remaining medication-free at five years.2
Contact: Alcon Laboratories (AUS) 1800 224 153 or (NZ) 0800 101 106
NZ-HDM-2300001
References
1. Samuelson, T.W. et al., A Schlemm’s canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: The HORIZON study. Ophthalmol 2019;126: 29-37.
2. Ahmed, I., et al., HORIZON Investigators. Long-term outcomes from the HORIZON randomized trial for a Schlemm’s canal microstent in combination cataract and glaucoma surgery. aojournal.org/article/S0161-6420(22)00160-9/fulltext.
3. Safety and effectiveness study of the Hydrus Microstent for lowering IOP in glaucoma patients. ClinTrials.gov (NCT01539239). *The five-year pivotal trial follow-up included 308 patients in the Hydrus group and 134 in the control.
